| 产品描述: | ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.
ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab . ML-T7 can be used for tumor immunotherapy research. |
| 体外研究: |
ML-T7 (10-50 mg/kg; 腹腔注射; every 2 days, 10 times) 抑制肿瘤生长并延长小鼠的生存期,对小鼠体重无不良影响[1]。 ML-T7 (20 mg/kg; 腹腔注射; every 2 days, 10 times)和 Nivolumab 联合治疗可提升 Nivolumab 抗体的抗肿瘤效果,同时可有效提高HCC小鼠存活率[1]。 ML-T7 (50 mg/kg, 腹腔注射; every 2 days for 3 weeks)在小鼠中表现出良好的安全性[1]。 |
| 体内研究: |
ML-T7(10 μM, 0-6 days) 通过Tim-3增强TCR/STAT5信号通路,促进CD8+细胞抗肿瘤活性。 ML-T7(10 μM, 24 h) 可通过Tim-3和Tim-4促进DC的成熟和功能,增强DC抗原呈递能力。 ML-T7(10 μM, 24 h) 增强CTL激活和细胞因子产生,减少CTLs的凋亡。 ML-T7(10 μM, 48 h) 可显著增强人NK 细胞系NK92细胞中IFN-γ、TNF-α、CD107a 和granzyme B的产生。 |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.975 ml |
9.875 ml |
19.75 ml |
| 5 mM |
0.395 ml |
1.975 ml |
3.95 ml |
| 10 mM |
0.197 ml |
0.987 ml |
1.975 ml |
| 50 mM |
0.039 ml |
0.197 ml |
0.395 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |